Kriya acquires NASH drug developer Tramontane

7 September 2023
kriya-company

Acquisitive US biotech Kriya Therapeutics yesterday revealed that it has acquired Tramontane Therapeutics, a private gene therapy company focused on developing treatments for metabolic and neurodegenerative diseases.

Tramontane, a spin out from Universitat Autònoma de Barcelona (UAB), is now a wholly-owned subsidiary of Kriya.

With the transaction, financial terms of which have not been disclosed, Kriya acquires a portfolio of fibroblast growth Factor 21 (FGF21) assets including Tramontane’s lead program, an adeno-associated virus (AAV) vector designed to express a steady level of the native FGF21 protein. FGF21 has beneficial metabolic effects across several target organs including the liver. Importantly, FGF21 has been established as a clinically-validated biological target in non-alcoholic steatohepatitis (NASH), which Kriya has prioritized as its lead FGF21 program.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology